TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for TLR4 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | TLR4 ECD-Fc Fusion Protein High purity (>95%), Endotoxin <0.1 EU/μg. HEK293 expressed (native glycosylation). Sequence Verified. Includes MD-2 binding domain. |
View TLR4 Products |
| Mutant Antigen | TLR4 D299G/T399I Mutant Proteins Hyporesponsive variants for polymorphism studies. Sequence Verified. |
View TLR4 Products |
| Co-receptor | MD-2/LY96 Protein Obligate binding partner for TLR4 ligand recognition. High purity. |
View MD-2 Products |
| Gene Delivery | TLR4 Lentivirus Particles Full-length ORF with MD-2 for stable reporter cell line construction. Functional validation via NF-κB reporter. |
View TLR4 Products |
| Benchmark Ab | Anti-TLR4 (NI-0101 Sequence) Recombinant neutralizing antibody control. Sequence Verified. |
View TLR4 Products |
| Validator | TLR4 siRNA Set For knockdown verification and specificity control. |
View TLR4 Products |
| Accessory Protein | CD14 Protein LPS transfer protein for complete TLR4 activation assay. |
View CD14 Products |
| Pathway Partner | MyD88 Protein Downstream adaptor protein for signaling studies. |
View MyD88 Products |
| Selectivity Control | TLR2 Protein Cross-species ortholog for TLR4 selectivity screening. |
View TLR2 Products |
Critical Assay Challenges & TarMart Advantages
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Endotoxin Contamination Risk (TLR4 detects LPS at pg/mL levels) | Ultra-low Endotoxin (<0.1 EU/μg) production in dedicated non-bacterial systems. Sequence Verified. |
| MD-2 Co-receptor Dependency | TLR4/MD-2 Heterodimer Complex available. HEK293 co‑expression validated. |
| Species-specific Ligand Recognition | Human/Mouse/Cyno ortholog proteins available with >95% purity for cross-reactivity testing and species-specific epitope mapping. |
| Conformational Receptor Activity | Lentivirus available for generating stable TLR4/MD-2 co-expressing reporter cell lines. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included (e.g., NI-0101). |
| False Positives in Inflammatory Assays | Validated siRNA included for specificity checks and background reduction. |
| Polymorphism Impact Assessment | D299G and T399I mutant proteins available for hypo‑responsive variant analysis. Sequence Verified. |
| TLR Family Selectivity (TLR2/TLR3/TLR5) | Homolog panel proteins (TLR2, TLR3, TLR5) strictly verified by mass spec for counter‑screening. |
Live TLR4/CD284 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for TLR4/CD284 therapeutics encompasses two main avenues: agonists for vaccine adjuvants and cancer immunotherapy, and antagonists for severe inflammatory conditions, sepsis, and autoimmune disorders. First‑generation systemic small molecules such as Eritoran and TAK‑242 encountered late‑phase setbacks, prompting a pivot toward biologics (monoclonal antibodies, fusion proteins) that offer superior selectivity and reduced off‑target TLR activation. The next wave focuses on localized delivery, precision medicine targeting specific TLR4 polymorphisms (e.g., D299G/T399I), and combination therapies with immune checkpoint inhibitors to overcome cold‑tumor resistance. Specific conformational inhibition of the TLR4/MD‑2 complex is a key strategy for improving safety and efficacy.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Agonists | GSK, Shionogi | Vaccine Adjuvants, Oncology | Reporter Cell Line (Need Lentivirus for stable expression) |
| Small Molecule Antagonists | Takeda (TAK‑242 – discontinued), Fujifilm (FP‑1001) | Sepsis, Ischemia | Cell permeability vs MD‑2 binding selectivity (Need full‑length Lentivirus cell lines) |
| Monoclonal Antibodies (Antagonist) | NovImmune (NI‑0101), Jiangsu Kanion (JKB‑121) | Rheumatoid Arthritis, Sepsis, ARDS, Colitis | High‑affinity ECD binding with MD‑2 competition (Need ultra‑pure TLR4/MD‑2 complex) |
| Peptide/Agonist | USC (MOTS‑c), Apeptico | Cancer Immunotherapy, Metabolic Disease, ARDS | Conformational activation assay (Need TLR4/MD‑2 cell lines with NF‑κB reporters) |
| Antibody‑Drug Conjugate | Emerging | Solid Tumors | Internalization + TLR4 activation (Need TLR4 ECD‑Fc and stable cell lines) |
Strategic Insights & Molecular Differentiation
TLR4 function is critically dependent on its co‑receptors MD‑2 and CD14. Drug candidates must be evaluated for binding affinity and specificity towards both the monomeric TLR4 ECD and the full TLR4/MD‑2 heterodimer. Species‑dependent differences in LPS analog recognition demand rigorous cross‑reactivity testing using human, mouse, and cynomolgus orthologs to ensure translational relevance. Furthermore, common polymorphisms (D299G/T399I) can alter signaling responses, requiring mutant proteins for variant‑specific assessment. Safety profiling for agonists must monitor cytokine release risk via whole‑blood assays and NF‑κB reporter systems. TarMart provides high‑purity recombinant proteins, lentiviral expression systems, and validated siRNA sets to address these challenges effectively.